{"id":50681,"date":"2025-03-06T18:24:37","date_gmt":"2025-03-06T10:24:37","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=50681"},"modified":"2025-08-11T17:58:34","modified_gmt":"2025-08-11T09:58:34","slug":"rucaparib-ag-014699pf-01367338-cas459868-92-9-apexbio-%e8%b2%a8%e8%99%9fa4156","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=50681","title":{"rendered":"Rucaparib (AG-014699,PF-01367338) | CAS#459868-92-9 APExBIO\u00a0 \u8ca8\u865fA4156\u00a0"},"content":{"rendered":"

PARP\u6291\u5236\u5291\u7cfb\u5217\u5546\u54c1->>Rucaparib (AG-014699,PF-01367338)<\/span><\/span><\/span><\/span><\/strong><\/p>\n

APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291(Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002<\/p>\n

<\/p>\n

<\/p>\n

Rucaparib (AG-014699,PF-01367338)| CAS#459868-92-9 APExBIO\u00a0 \u8ca8\u865fA4156\u00a0<\/a><\/span><\/p>\n

Potent PARP inhibitor<\/p>\n

Rucaparib\uff0c\u4e5f\u7a31\u70ba AG-014699 \u6216 PF-01367338\uff0c\u662f\u4e00\u7a2e\u805a\uff08ADP \u6838\u7cd6\uff09\u805a\u5408\u9176\uff08PARP\uff09\u6291\u5236\u5291\u3002 PARP \u662f\u4e00\u7a2e DNA \u640d\u50b7\u6fc0\u6d3b\u6838\u9176( DNA damage-activated nuclear enzyme)\uff0c\u5728\u9e7c\u57fa\u5207\u9664\u4fee\u5fa9\u9014\u5f91\u4e2d\u5177\u6709\u95dc\u9375\u7684\u4fe1\u865f\u50b3\u5c0e\u4f5c\u7528\u3002\u56e0\u6b64\uff0crucaparib \u4e5f\u88ab\u767c\u73fe\u5c0d DNA \u4fee\u5fa9\u7f3a\u9677\u7684\u7d30\u80de\u6700\u6709\u6548\uff0c\u9019\u4e9b\u7d30\u80de\u7f3a\u9677\u662f\u7531\u65bc\u66b4\u9732\u65bc\u57fa\u56e0\u6bd2\u6027\u5291\u800c\u5f15\u8d77\u7684\uff0c\u4f8b\u5982\u8f3b\u5c04\u6703\u7522\u751f DNA \u640d\u50b7\uff0c\u7576 DNA \u4fee\u5fa9\u53d7\u640d\u6642\uff0c\u5176\u6bd2\u6027\u6703\u589e\u5f37\u3002 rucaparib \u5b58\u5728\u4e0b\u653e\u5c04\u654f\u611f\u6027\u7684\u589e\u52a0\u8207 \u03b3-H2AX \u548c p53BP1 \u7126\u9ede\u78ba\u5b9a\u7684\u6301\u7e8c\u6027 DNA \u65b7\u88c2\u6709\u95dc\u3002 Rucaparib \u4f7f\u524d\u5217\u817a\u764c\u7d30\u80de\u653e\u5c04\u589e\u654f\uff0c\u6700\u6709\u6548\u7684\u662f\u90a3\u4e9b PTEN \u7f3a\u9677\u4e26\u8868\u9054 ETS \u57fa\u56e0\u878d\u5408\u86cb\u767d(ETS gene fusion proteins)\u7684\u7d30\u80de\uff0c\u8a72\u86cb\u767d\u6291\u5236 NHEJ DNA \u4fee\u5fa9 (NHEJ DNA repair)\u3002<\/p>\n

<\/p>\n

<\/p>\n

References<\/em><\/p>\n

Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott, Mark R. Middleton, Richard H. Wilson, Evan Mulligan, Nicola Curtin, Diane Wang, Raz Dewji, Antonello Abbattista, Jorge Gallo, Hilary Calvert. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.<\/em><\/p>\n

Payel Chatterjee, Gaurav Choudhary, Warren D. Heston, Eric A. Klein, Alex Almasan. The PARP inhibitor rucaparib radiosensitizes prostate cancer cells, most effectively those that are PTEN-deficient and are expressing ETS gene fusion proteins, which inhibit NHEJ DNA repair. Cancer Research. 2012. 72: B27.<\/em><\/p>\n

<\/p>\n

Chemical structure<\/span><\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Physical Appearance<\/td>\nA solid<\/td>\n<\/tr>\n
Storage<\/td>\nStore at -20\u00b0C<\/td>\n<\/tr>\n
M.Wt<\/td>\n421.36<\/td>\n<\/tr>\n
Cas No.<\/td>\n459868-92-9<\/td>\n<\/tr>\n
Formula<\/td>\nC19<\/sub>H18<\/sub>FN3<\/sub>O\u00b7H3<\/sub>PO4<\/sub><\/td>\n<\/tr>\n
Synonyms<\/td>\nRucaparib phosphate,AG-14699,AG 014699<\/td>\n<\/tr>\n
Solubility<\/td>\n\u226521.08 mg\/mL in DMSO; insoluble in EtOH; insoluble in H2O<\/td>\n<\/tr>\n
Chemical Name<\/td>\n8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one phosphate<\/td>\n<\/tr>\n
SDF<\/td>\nDownload SDF<\/a><\/td>\n<\/tr>\n
Canonical SMILES<\/td>\nOP(O)(O)=O.FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1<\/td>\n<\/tr>\n
Shipping Condition<\/td>\nSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.<\/td>\n<\/tr>\n
General tips<\/td>\nWe do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n

Product Citation<\/span><\/h2>\n<\/div>\n
\n
\n

1. John P. Brabson, Tiffany Leesang, et al. “Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia.” Cell Reports 42, 112027 January 31, 2023.<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/span><\/h2>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\u54c1\u9805<\/td>\nCAS#<\/td>\n#\u8ca8\u865f<\/td>\n\u61c9\u7528<\/td>\n<\/tr>\n
Z-VAD-FMK \u00a0<\/a><\/td>\nCAS# 187389-52-2<\/td>\n\u8ca8\u865f\u00a0A1902<\/td>\n\n

Proteases<\/p>\n

ICE-like proteases<\/td>\n<\/tr>\n

TAPI-1 \u00a0<\/a><\/td>\nCAS#171235-71-5<\/td>\n\u8ca8\u865f\u00a0B4686<\/td>\n\n

Proteases<\/p>\n

TACE\/ADAM17 inhibitor Product Citation+3<\/td>\n<\/tr>\n

Talabostat mesylate<\/a><\/td>\nCAS# 150080-09-4<\/td>\n\u8ca8\u865fB3941<\/td>\n\n

Proteases<\/p>\n

DPP4 \u4e8c\u80bd\u57fa\u80bd\u9176\u7279\u7570\u6027\u6291\u5236\u5291<\/td>\n<\/tr>\n

Z-IETD-FMK<\/a><\/td>\nCAS# 210344-98-2<\/td>\n\u8ca8\u865fB3232<\/td>\ninhibitor of caspase 8<\/td>\n<\/tr>\n
Cisplatin<\/a><\/td>\nCAS# 15663-27-1<\/td>\n\u8ca8\u865fA8321<\/td>\n\u9ad8\u6548\u3001\u5ee3\u8b5c\u7684\u5316\u7642\u85e5\u7269<\/td>\n<\/tr>\n
17-DMAG (Alvespimycin) HCl<\/a><\/td>\nCAS#467214-21-7<\/td>\n\u00a0\u8ca8\u865fA2213<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
CA-074 Me\u00a0<\/a><\/td>\nCAS# 147859-80-1<\/td>\n\u8ca8\u865fA8239<\/td>\nCathepsin B inhibitor<\/td>\n<\/tr>\n
VX-765<\/a><\/td>\nCAS# 273404-37-8<\/td>\n\u8ca8\u865fA8238<\/td>\nCaspase-1 inhibitor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
A4108<\/td>\nResminostat (RAS2410)<\/td>\n864814-88-0<\/td>\n98.00%<\/td>\nPotent HDAC inhibitor<\/td>\n<\/tr>\n
A4110<\/td>\nMLN8237 (Alisertib)<\/td>\n1028486-01-2<\/td>\n98.77%<\/td>\nAurora A Kinase inhibitor, Potent and selective<\/td>\n<\/tr>\n
A4111<\/td>\nVX-680 (MK-0457,Tozasertib)<\/td>\n639089-54-6<\/td>\n99.93%<\/td>\nAurora kinase inhibitor<\/td>\n<\/tr>\n
A4112<\/td>\nBarasertib (AZD1152-HQPA)<\/td>\n722544-51-6<\/td>\n98.25%<\/td>\nAurora Kinase B inhibitor, Potent and selective<\/td>\n<\/tr>\n
A4113<\/td>\nZM 447439<\/td>\n331771-20-1<\/td>\n98.80%<\/td>\nAurora Kinase inhibitor,potent and selective<\/td>\n<\/tr>\n
A4114<\/td>\nMLN8054<\/td>\n869363-13-3<\/td>\n97.64%<\/td>\nAurora A inhibitor<\/td>\n<\/tr>\n
A4115<\/td>\nJNJ-7706621<\/td>\n443797-96-4<\/td>\n98.11%<\/td>\nPotent CDK\/Aurora kinase inhibitor<\/td>\n<\/tr>\n
A4116<\/td>\nDanusertib (PHA-739358)<\/td>\n827318-97-8<\/td>\n99.39%<\/td>\nPan-aurora kinase inhibitor<\/td>\n<\/tr>\n
A4117<\/td>\nAT9283<\/td>\n896466-04-9<\/td>\n99.29%<\/td>\nAurora kinase\/JAK inhibitor<\/td>\n<\/tr>\n
A4118<\/td>\nHesperadin<\/td>\n422513-13-1<\/td>\n98.29%<\/td>\nAurora B kinase inhibitor<\/td>\n<\/tr>\n
A4119<\/td>\nAMG-900<\/td>\n945595-80-2<\/td>\n98.99%<\/td>\nAurora kinase inhibitor<\/td>\n<\/tr>\n
A4120<\/td>\nMK-5108 (VX-689)<\/td>\n1010085-13-8<\/td>\n96.91%<\/td>\nAurora-A kinase inhibitor,highly selective<\/td>\n<\/tr>\n
A4121<\/td>\nSNS-314 Mesylate<\/td>\n1146618-41-8<\/td>\n99.94%<\/td>\nAurora A\/B\/C kinases inhibitor, potent and selective<\/td>\n<\/tr>\n
A4122<\/td>\nPHA-680632<\/td>\n398493-79-3<\/td>\n98.53%<\/td>\nAurora kinase inhibitor,novel and potent<\/td>\n<\/tr>\n
A4123<\/td>\nKW 2449<\/td>\n1000669-72-6<\/td>\n99.94%<\/td>\nMultikinase inhibitor<\/td>\n<\/tr>\n
A4124<\/td>\nTAK-901<\/td>\n934541-31-8<\/td>\n98.00%<\/td>\nNovel Aurora A\/B inhibitor<\/td>\n<\/tr>\n
A4125<\/td>\nCYC116<\/td>\n693228-63-6<\/td>\n98.71%<\/td>\nPotent Aurora A\/B inhibitor<\/td>\n<\/tr>\n
A4126<\/td>\nAurora A Inhibitor I<\/td>\n1158838-45-9<\/td>\n98.83%<\/td>\nAurora A inhibitor<\/td>\n<\/tr>\n
A4127<\/td>\nGSK1070916<\/td>\n942918-07-2<\/td>\n98.00%<\/td>\nAurora B\/C inhibitor<\/td>\n<\/tr>\n
A4128<\/td>\nPF-03814735<\/td>\n942487-16-3<\/td>\n98.00%<\/td>\nAurora A\/B inhibitor<\/td>\n<\/tr>\n
A4129<\/td>\nENMD-2076 L-(+)-Tartaric acid<\/td>\n1291074-87-7<\/td>\n99.36%<\/td>\nAurora kinases inhibitor<\/td>\n<\/tr>\n
A4130<\/td>\nENMD-2076<\/td>\n934353-76-1<\/td>\n98.78%<\/td>\nSelective Aurora A\/Flt3 inhibitor<\/td>\n<\/tr>\n
A4132<\/td>\nCCT137690<\/td>\n1095382-05-0<\/td>\n98.00%<\/td>\nAurora A\/B\/C inhibitor<\/td>\n<\/tr>\n
A4135<\/td>\nTofacitinib (CP-690550) Citrate<\/td>\n540737-29-9<\/td>\n99.64%<\/td>\nPotent JAK inhibitor<\/td>\n<\/tr>\n
A4136<\/td>\nTG101348 (SAR302503)<\/td>\n936091-26-8<\/td>\n99.39%<\/td>\nJAK-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4137<\/td>\nAZD1480<\/td>\n935666-88-9<\/td>\n99.31%<\/td>\nJAK2 inhibitor,ATP-competitive and novel<\/td>\n<\/tr>\n
A4138<\/td>\nTofacitinib (CP-690550,Tasocitinib)<\/td>\n477600-75-2<\/td>\n99.94%<\/td>\nJanus kinase inhibitor<\/td>\n<\/tr>\n
A4139<\/td>\nAG-490<\/td>\n133550-30-8<\/td>\n99.76%<\/td>\nJAK2\/EGFR inhibitor<\/td>\n<\/tr>\n
A4140<\/td>\nWP1066<\/td>\n857064-38-1<\/td>\n99.84%<\/td>\nJAK2\/STAT3 inhibitor,cell-permeable<\/td>\n<\/tr>\n
A4141<\/td>\nBaricitinib (LY3009104, INCB028050)<\/td>\n1187594-09-7<\/td>\n98.06%<\/td>\nJAK1\/JAK2 inhibitor,selective orally bioavailable<\/td>\n<\/tr>\n
A4143<\/td>\nCYT387<\/td>\n1056634-68-4<\/td>\n98.70%<\/td>\nJAK-1\/-2 inhibitor,ATP competitive<\/td>\n<\/tr>\n
A4144<\/td>\nAZ 960<\/td>\n905586-69-8<\/td>\n98.00%<\/td>\nJAKs inhibitor<\/td>\n<\/tr>\n
A4145<\/td>\nTG101209<\/td>\n936091-14-4<\/td>\n99.46%<\/td>\nJAK2\/3 inhibitor<\/td>\n<\/tr>\n
A4146<\/td>\nCEP-33779<\/td>\n1257704-57-6<\/td>\n98.00%<\/td>\nJAK2 inhibitor,highly selective<\/td>\n<\/tr>\n
A4147<\/td>\nLY2784544<\/td>\n1229236-86-5<\/td>\n98.00%<\/td>\nJAK2 inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A4148<\/td>\nNVP-BSK805 2HCl<\/td>\n1092499-93-8 (free base)<\/td>\n99.23%<\/td>\nJAK2 inhibitor<\/td>\n<\/tr>\n
A4149<\/td>\nS-Ruxolitinib (INCB018424)<\/td>\n941685-37-6<\/td>\n99.34%<\/td>\nJAK1\/2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4150<\/td>\nWHI-P154<\/td>\n211555-04-3<\/td>\n99.19%<\/td>\nJAK3 inhibitor<\/td>\n<\/tr>\n
A4151<\/td>\nZM 39923 HCl<\/td>\n1021868-92-7<\/td>\n99.91%<\/td>\nJAK3 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4152<\/td>\nBMS-911543<\/td>\n1271022-90-2<\/td>\n98.41%<\/td>\nJAK2 inhibitor,selective small molecule<\/td>\n<\/tr>\n
A4153<\/td>\nBMN 673<\/td>\n1207456-01-6<\/td>\n99.26%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4154<\/td>\nOlaparib (AZD2281, Ku-0059436)<\/td>\n763113-22-0<\/td>\n99.80%<\/td>\nPotent PARP1\/PARP2 inhibitor<\/td>\n<\/tr>\n
A4156<\/td>\nRucaparib (AG-014699,PF-01367338)<\/td>\n459868-92-9<\/td>\n98.46%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4157<\/td>\nIniparib (BSI-201)<\/td>\n160003-66-7<\/td>\n99.08%<\/td>\nPARP1 inhibitor,intravenously adminsitered<\/td>\n<\/tr>\n
A4158<\/td>\nAG-14361<\/td>\n328543-09-5<\/td>\n99.17%<\/td>\nPotent PARP1 inhibitor<\/td>\n<\/tr>\n
A4159<\/td>\nPJ34 hydrochloride<\/td>\n344458-15-7<\/td>\n99.54%<\/td>\nPARP inhibitor,potent and cell-permeable<\/td>\n<\/tr>\n
A4160<\/td>\nA-966492<\/td>\n934162-61-5<\/td>\n99.03%<\/td>\nPARP-1\/-2 inhibitor, highly potent<\/td>\n<\/tr>\n
A4161<\/td>\n3-aminobenzamide<\/td>\n3544-24-9<\/td>\n99.66%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4163<\/td>\nUPF 1069<\/td>\n1048371-03-4<\/td>\n98.00%<\/td>\nSelective PARP2 inhibitor<\/td>\n<\/tr>\n
A4164<\/td>\nAZD2461<\/td>\n1174043-16-3<\/td>\n98.00%<\/td>\nNovel PARP inhibitor<\/td>\n<\/tr>\n
A4166<\/td>\nEPZ5676<\/td>\n1380288-87-8<\/td>\n99.28%<\/td>\nDOT1L inhibitor,potent and SAM competitive<\/td>\n<\/tr>\n
A4167<\/td>\nSGC 0946<\/td>\n1561178-17-3<\/td>\n99.65%<\/td>\nDOT1L inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A4168<\/td>\nEntacapone<\/td>\n130929-57-6<\/td>\n99.28%<\/td>\nCOMT inhibitor<\/td>\n<\/tr>\n
A4170<\/td>\nEPZ004777<\/td>\n1338466-77-5<\/td>\n99.43%<\/td>\nDOT1L inhibitor<\/td>\n<\/tr>\n
A4171<\/td>\nEPZ005687<\/td>\n1396772-26-1<\/td>\n98.66%<\/td>\nEZH2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4176<\/td>\nThioguanine<\/td>\n154-42-7<\/td>\n98.18%<\/td>\nPurine antimetabolite<\/td>\n<\/tr>\n
A4180<\/td>\nSRT1720 HCl<\/td>\n1001645-58-4<\/td>\n99.52%<\/td>\nSIRT1 activator<\/td>\n<\/tr>\n
A4181<\/td>\nEX 527 (SEN0014196)<\/td>\n49843-98-3<\/td>\n99.71%<\/td>\nSIRT1 inhibitor<\/td>\n<\/tr>\n
A4182<\/td>\nResveratrol<\/td>\n501-36-0<\/td>\n99.94%<\/td>\nSIRT1 activator<\/td>\n<\/tr>\n
A4183<\/td>\nSirtinol<\/td>\n410536-97-9<\/td>\n98.00%<\/td>\nSIRT inhibitor<\/td>\n<\/tr>\n
A4184<\/td>\nPFI-1 (PF-6405761)<\/td>\n1403764-72-6<\/td>\n97.20%<\/td>\nBET inhibitor<\/td>\n<\/tr>\n
A4186<\/td>\nBromosporine<\/td>\n1619994-69-2<\/td>\n98.00%<\/td>\nBromodomain inhibitor,non-selective<\/td>\n<\/tr>\n
A4187<\/td>\nFG-4592 (ASP1517)<\/td>\n808118-40-3<\/td>\n99.92%<\/td>\nHIF prolyl-hydroxylase inhibitor<\/td>\n<\/tr>\n
A4188<\/td>\n2-Methoxyestradiol (2-MeOE2)<\/td>\n362-07-2<\/td>\n99.00%<\/td>\nApoptotic, antiproliferative and antiangiogenic agent<\/td>\n<\/tr>\n
A4189<\/td>\nIOX2(Glycine)<\/td>\n931398-72-0<\/td>\n98.10%<\/td>\nHIF-1\u03b1 prolyl hydroxylase-2 (PHD2) inhibitor<\/td>\n<\/tr>\n
A4190<\/td>\nGSK J4 HCl<\/td>\n1373423-53-0(free base)<\/td>\n98.00%<\/td>\nInhibitor of H3K27 demethylase JMJD3,potent and cell-permeable<\/td>\n<\/tr>\n
A4191<\/td>\nGSK J1<\/td>\n1373422-53-7<\/td>\n99.50%<\/td>\nH3K27 demethylase JMJD3 inhibitor<\/td>\n<\/tr>\n
A4192<\/td>\nSGI-1776 free base<\/td>\n1025065-69-3<\/td>\n99.19%<\/td>\nPim kinase inhibitor,ATP-competitive<\/td>\n<\/tr>\n
A4193<\/td>\nSMI-4a<\/td>\n438190-29-5<\/td>\n99.76%<\/td>\nPotent Pim inhibitor<\/td>\n<\/tr>\n
A4194<\/td>\nObatoclax mesylate (GX15-070)<\/td>\n803712-79-0<\/td>\n98.49%<\/td>\nPotent Bcl-2 inhibitor<\/td>\n<\/tr>\n
A4199<\/td>\nSabutoclax<\/td>\n1228108-65-3<\/td>\n98.00%<\/td>\npan-Bcl-2 inhibitor<\/td>\n<\/tr>\n
A4200<\/td>\nApogossypolone (ApoG2)<\/td>\n886578-07-0<\/td>\n98.00%<\/td>\nBcl-2 inhibitor,nonpeptidic small molecule<\/td>\n<\/tr>\n
A4202<\/td>\nRITA (NSC 652287)<\/td>\n213261-59-7<\/td>\n99.53%<\/td>\nMdm2-p53 interaction and p53 ubiquitination blocking<\/td>\n<\/tr>\n
A4203<\/td>\nTenovin-1<\/td>\n380315-80-0<\/td>\n99.90%<\/td>\nSIRT2 inhibitor, activates p53<\/td>\n<\/tr>\n
A4204<\/td>\nJNJ-26854165 (Serdemetan)<\/td>\n881202-45-5<\/td>\n98.35%<\/td>\nP53 activator, blocking Mdm2-p53 interaction<\/td>\n<\/tr>\n
A4206<\/td>\nPifithrin-\u03b1 (PFT\u03b1)<\/td>\n63208-82-2<\/td>\n98.16%<\/td>\np53 inhibitor<\/td>\n<\/tr>\n
A4208<\/td>\nNSC 319726<\/td>\n71555-25-4<\/td>\n98.00%<\/td>\nReactivator of mutant p53<\/td>\n<\/tr>\n
A4209<\/td>\nNSC 207895 (XI-006)<\/td>\n58131-57-0<\/td>\n98.00%<\/td>\nMDMX inhibitor,anti-cancer agent<\/td>\n<\/tr>\n
A4210<\/td>\nBay 11-7821 (BAY 11-7082)<\/td>\n19542-67-7<\/td>\n99.91%<\/td>\nIKK\/NF-\u03baB\/TNF\u03b1 inhibitor<\/td>\n<\/tr>\n
A4211<\/td>\nLenalidomide (CC-5013)<\/td>\n191732-72-6<\/td>\n98.66%<\/td>\nAntineoplastic agent,inhibits angiogenesis<\/td>\n<\/tr>\n
A4212<\/td>\nPomalidomide (CC-4047)<\/td>\n19171-19-8<\/td>\n98.46%<\/td>\nImmunomodulator,antumor\/anti-angiogenic<\/td>\n<\/tr>\n
A4213<\/td>\nNecrostatin-1<\/td>\n4311-88-0<\/td>\n99.88%<\/td>\nRIP1 inhibitor<\/td>\n<\/tr>\n
A4216<\/td>\nThalidomide<\/td>\n50-35-1<\/td>\n99.21%<\/td>\nImmunomodulatory agent,sedative drug,angiogenesis inhibitor<\/td>\n<\/tr>\n
A4217<\/td>\nQNZ (EVP4593)<\/td>\n545380-34-5<\/td>\n99.41%<\/td>\nPotent NF-\u03baB inhibitor<\/td>\n<\/tr>\n
A4219<\/td>\nBirinapant (TL32711)<\/td>\n1260251-31-7<\/td>\n98.13%<\/td>\nPotent XIAP\/cIAP1 antagonist<\/td>\n<\/tr>\n
A4221<\/td>\nYM155<\/td>\n781661-94-7<\/td>\n99.60%<\/td>\nSurvivin suppressant,apoptosis inhibitor<\/td>\n<\/tr>\n
A4224<\/td>\nGDC-0152<\/td>\n873652-48-3<\/td>\n99.00%<\/td>\nIAP antagonist,potent amd samll-molecule<\/td>\n<\/tr>\n
A4227<\/td>\nTipifarnib (Zarnestra)<\/td>\n192185-72-1<\/td>\n99.18%<\/td>\nFarnesyltransferase inhibitor,potent and specific<\/td>\n<\/tr>\n
A4228<\/td>\nNutlin-3<\/td>\n890090-75-2<\/td>\n98.35%<\/td>\nMDM2 antagonist,inhibits MDM2-p53 interaction<\/td>\n<\/tr>\n
A4230<\/td>\nNSC 66811<\/td>\n6964-62-1<\/td>\n98.00%<\/td>\nMDM2 inhibitor<\/td>\n<\/tr>\n
A4232<\/td>\nCyclophosphamide monohydrate<\/td>\n6055-19-2<\/td>\n98.00%<\/td>\nalkylating, cytotoxic agent,antitumor activity<\/td>\n<\/tr>\n
A4233<\/td>\nMethylprednisolone<\/td>\n83-43-2<\/td>\n99.31%<\/td>\nApoptosis inducer,GR agonist<\/td>\n<\/tr>\n
A4234<\/td>\nTW-37<\/td>\n877877-35-5<\/td>\n98.13%<\/td>\nBcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1<\/td>\n<\/tr>\n
A4237<\/td>\nAmuvatinib (MP-470, HPK 56)<\/td>\n850879-09-3<\/td>\n99.91%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
A4240<\/td>\nAbiraterone<\/td>\n154229-19-3<\/td>\n99.30%<\/td>\nPotent CYP17 inhibitor<\/td>\n<\/tr>\n
A4300<\/td>\nGW9662<\/td>\n22978-25-2<\/td>\n99.25%<\/td>\nPPAR\u03b3 antagonist<\/td>\n<\/tr>\n
A4301<\/td>\nT0070907<\/td>\n313516-66-4<\/td>\n99.88%<\/td>\nHuman PPAR\u03b3 antagonist,potent and selective<\/td>\n<\/tr>\n
A4302<\/td>\nRosiglitazone maleate<\/td>\n155141-29-0<\/td>\n99.15%<\/td>\nPPAR\u03b3 agonist,high-affinity and selective,potent insulin sensitizer<\/td>\n<\/tr>\n
A4303<\/td>\nGSK3787<\/td>\n188591-46-0<\/td>\n99.73%<\/td>\nPPAR\u03b2\/\u03b4 antagonist,novel and irreversible<\/td>\n<\/tr>\n
A4304<\/td>\nRosiglitazone<\/td>\n122320-73-4<\/td>\n99.80%<\/td>\nPotent PPAR\u03b3 agonist<\/td>\n<\/tr>\n
A4305<\/td>\nWY-14643 (Pirinixic Acid)<\/td>\n50892-23-4<\/td>\n99.87%<\/td>\nPPAR\u03b1 agonist,selective and highly potent<\/td>\n<\/tr>\n
A4306<\/td>\nCiprofibrate<\/td>\n52214-84-3<\/td>\n98.88%<\/td>\nPPAR\u03b1 agonist<\/td>\n<\/tr>\n
A4307<\/td>\nGW0742<\/td>\n317318-84-6<\/td>\n99.64%<\/td>\nPPAR\u03b4\/\u03b2 agonist,potent and selective<\/td>\n<\/tr>\n
A4308<\/td>\nAlizarin<\/td>\n72-48-0<\/td>\n98.03%<\/td>\nChelator for calcium,used to stain calcium deposites,Alizarin complexone is used for bone staining to study bone remodeling<\/td>\n<\/tr>\n
A4309<\/td>\nGW501516<\/td>\n317318-70-0<\/td>\n98.27%<\/td>\nPPAR\u03b4 agonist,selective and potent<\/td>\n<\/tr>\n
A4310<\/td>\nRosiglitazone HCl<\/td>\n302543-62-0<\/td>\n99.31%<\/td>\nPPAR\u03b3 agonist<\/td>\n<\/tr>\n
A4311<\/td>\nPF-4981517<\/td>\n1390637-82-7<\/td>\n98.00%<\/td>\nCYP3A4 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4313<\/td>\nCobicistat (GS-9350)<\/td>\n1004316-88-4<\/td>\n99.94%<\/td>\nSelective CYP3A inhibitor<\/td>\n<\/tr>\n
A4316<\/td>\nKetoconazole<\/td>\n65277-42-1<\/td>\n99.48%<\/td>\nInhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase<\/td>\n<\/tr>\n
A4317<\/td>\nApremilast (CC-10004)<\/td>\n608141-41-9<\/td>\n98.98%<\/td>\nPDE4 inhibitor<\/td>\n<\/tr>\n
A4318<\/td>\nAvasimibe<\/td>\n166518-60-1<\/td>\n99.66%<\/td>\nACAT inhibitor,orally bioavailable<\/td>\n<\/tr>\n
A4319<\/td>\nRoflumilast<\/td>\n162401-32-3<\/td>\n99.08%<\/td>\nPDE-4 inhibitor<\/td>\n<\/tr>\n
A4320<\/td>\nVoriconazole<\/td>\n137234-62-9<\/td>\n99.96%<\/td>\nCYP51 inhibitor<\/td>\n<\/tr>\n
A4321<\/td>\nSildenafil Citrate<\/td>\n171599-83-0<\/td>\n99.63%<\/td>\nTreat erectile dysfunction and PAH<\/td>\n<\/tr>\n
A4322<\/td>\nClarithromycin<\/td>\n81103-11-9<\/td>\n99.39%<\/td>\nCYP3A inhibitor, potent<\/td>\n<\/tr>\n
A4323<\/td>\nVardenafil HCl Trihydrate<\/td>\n330808-88-3<\/td>\n99.63%<\/td>\nPDE5 inhibitor, potent and selective<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

PARP\u6291\u5236\u5291\u7cfb\u5217\u5546\u54c1->>Rucaparib (AG-014699,PF-01367338) A […]<\/p>\n","protected":false},"author":3,"featured_media":47343,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368],"tags":[6956],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50681"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50681"}],"version-history":[{"count":4,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50681\/revisions"}],"predecessor-version":[{"id":51779,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50681\/revisions\/51779"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/47343"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}